KPV Peptide

What is KPV?

KPV is a three amino acid peptide, Lysine-Proline-Valine, that forms the C-terminal end of the hormone alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers isolated this fragment because it appears to carry part of alpha-MSH's anti-inflammatory activity without the pigment-signaling effects of the full hormone (Kannengiesser et al., 2008). In laboratory work it is written as Lys-Pro-Val or KPV.

The interest is narrow and specific: KPV is studied as a signaling molecule that dampens inflammatory pathways inside epithelial and immune cells. It is not a growth peptide, not a metabolic peptide, and not a hormone in its own right.

How does KPV work in research models?

KPV enters cells through the peptide transporter PepT1 and then interferes with pro-inflammatory signaling, based on cell and animal studies (Dalmasso et al., 2008). PepT1 is a transporter normally expressed in the small intestine and upregulated in inflamed colon tissue. Because KPV is small, it can be carried directly into intestinal epithelial cells and immune cells through this route rather than acting only at a surface receptor.

Once inside, KPV has been reported to reduce activation of NF-kB and MAPK, two signaling systems that drive the production of inflammatory cytokines (Kannengiesser et al., 2008). In mouse colitis models, this translated to lower inflammatory markers and reduced tissue damage (Dalmasso et al., 2008). The proposed benefit of the tripeptide over full alpha-MSH is size and simplicity: a smaller molecule that keeps the anti-inflammatory signal and travels through an existing transporter.

Important limit: these are mechanistic and animal findings. No human study has confirmed that the same uptake and signaling happen at a clinically meaningful level in people.

What does the published research actually show?

The two core studies are in cell lines and mice, and both report anti-inflammatory effects rather than clinical outcomes.

That is the depth of the primary evidence base for KPV as an anti-inflammatory tripeptide. Both papers are consistent in direction, both are preclinical, and neither can tell you how KPV behaves in a human body.

Is there any human data on KPV?

No. There are zero completed human trials of KPV for any indication. Any statement about human dosing, human safety, or human benefit is extrapolation from mouse and cell studies (Kannengiesser et al., 2008; Dalmasso et al., 2008). This is the single most important thing to understand about KPV: the mechanism is documented, the human evidence is not.

What doses has research reported?

There is no established human dose for KPV, and the published work uses cell-culture concentrations and animal delivery systems, not human protocols.

Because no human dose exists, PL does not publish one. Any decision about whether a research compound is appropriate for a person belongs to a qualified clinician, not a webpage.

How does KPV compare to larazotide and LL-37?

KPV, larazotide, and LL-37 are all discussed in the anti-inflammatory and gut-barrier research space, but they work through separate mechanisms. KPV acts inside cells on NF-kB and MAPK signaling after PepT1 uptake (Dalmasso et al., 2008). Larazotide is studied as a tight-junction regulator that acts on the gut barrier. LL-37 is an antimicrobial peptide with immune-modulating roles. If you are comparing anti-inflammatory research peptides, treat them as different tools with different evidence bases rather than interchangeable options. See the linked hubs below.

What side effects or risks are reported?

There is no human safety dataset for KPV, so no side effect profile can be stated with confidence. The animal and cell studies focused on efficacy signals, not systematic toxicity screening (Kannengiesser et al., 2008; Dalmasso et al., 2008). Absence of reported harm in a small preclinical literature is not evidence of safety in humans. This is a research compound, and risk in people is unknown.